Lanreotide supply disruption
Supply issues at partner site will reduce Q3 lanreotide sales significantly; recovery depends on partner's production ramp-up.
CIPLA / Q2-FY25 / risks
Keep the risk register visible.
Cipla · Material risks, their source context, and severity in the latest available quarter.
Research layer active
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Risk intelligence
Material risks this quarter
high
Goa facility FDA classification uncertainty
Goa facility received Form 483 observations; classification still awaited, which could impact Abraxane launch timeline and other approvals.
US generic pricing erosion
Blended US price erosion of ~10% YoY, with potential for further pressure from new competition in Albuterol and other products.
India acute season weakness
Slow seasonal growth in acute category, especially anti-infectives, impacted India business; recovery dependent on respiratory season.